Antihyperlipidemic effect of tyrosol, a phenolic compound in streptozotocin-induced diabetic rats

Toxicol Mech Methods. 2021 Sep;31(7):507-516. doi: 10.1080/15376516.2021.1926030. Epub 2021 Jun 28.

Abstract

We investigated the antihyperlipidemic effects of tyrosol in streptozotocin (STZ)-induced diabetic rats. Rats were injected intraperitoneally with STZ (40 mg/kg), and these established experimental rats were treated with tyrosol (20 mg/kg) and glibenclamide (600 µg/kg) for 45 days. The observed results revealed that tyrosol treatment significantly reduced plasma glucose, plasma, and liver total cholesterol, triglycerides, free fatty acids, phospholipids, plasma low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, atherogenic index, and significantly increased plasma insulin and high-density lipoprotein cholesterol in STZ-induced diabetic rats. The activity of 3-hydroxy 3-methylglutaryl coenzyme A reductase significantly reduced in the liver, whereas the activities of lipoprotein lipase and lecithin cholesterol acyltransferase were significantly increased in the plasma of tyrosol treated STZ-induced diabetic rats. Histological examination showed that tyrosol treatment remarkably reduced lipid accumulation in the liver of STZ-induced diabetic rats. The present study revealed that tyrosol exhibits potent antihyperlipidemic effects in STZ-induced diabetic rats.

Keywords: Diabetes mellitus; insulin; lipids; streptozotocin; tyrosol.

MeSH terms

  • Animals
  • Blood Glucose
  • Diabetes Mellitus, Experimental* / drug therapy
  • Hypoglycemic Agents / therapeutic use
  • Hypolipidemic Agents / therapeutic use
  • Phenylethyl Alcohol / analogs & derivatives
  • Rats
  • Streptozocin
  • Triglycerides

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Triglycerides
  • 4-hydroxyphenylethanol
  • Streptozocin
  • Phenylethyl Alcohol